Novavax (NVAX)
(Delayed Data from NSDQ)
$14.40 USD
+1.50 (11.63%)
Updated May 16, 2024 04:00 PM ET
After-Market: $14.33 -0.07 (-0.49%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$14.40 USD
+1.50 (11.63%)
Updated May 16, 2024 04:00 PM ET
After-Market: $14.33 -0.07 (-0.49%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Zacks News
Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
by Ekta Bagri
Novavax, Inc (NVAX) and Fulcrum Therapeutics, Inc (FULC) are in the spotlight following license agreements with pharma giant Sanofi.
Zacks Investment Ideas feature highlights: GameStop, AMC, Novavax, S&P 500 Index ETF and Nvidia
by Zacks Equity Research
GameStop, AMC, Novavax, S&P 500 Index ETF and Nvidia have been highlighted in this Investment Ideas article.
Zacks Investment Ideas feature highlights: GameStop, AMC, Novavax, Reddit and Tesla
by Zacks Equity Research
GameStop, AMC, Novavax, Reddit and Tesla have been highlighted in this Investment Ideas article.
Novavax (NVAX) Q1 Earnings Miss, Stock Soars on Sanofi Deal
by Zacks Equity Research
Novavax (NVAX) partners with Sanofi to market its COVID-19 vaccine and also develop novel COVID-19-influenza combination vaccines. This announcement even overshadows the dismal Q1 results.
Meme Mania is Back: Buy these 3 Stocks
by Andrew Rocco
Monday's market action tells us that meme stocks are back in play. However, because not all meme stocks are created equally, investors should focus on those with fundamental catalysts.
Company News For May 13, 2024
by Zacks Equity Research
Companies In The Article Are:NVAX, SNY, MRNA, G and IAG.
Novavax (NVAX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Novavax (NVAX) delivered earnings and revenue surprises of -0.96% and 7.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Novavax (NVAX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Novavax (NVAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $4.33, marking a +0.93% move from the previous day.
What's in the Cards for Amgen (AMGN) This Earnings Season?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?
by Zacks Equity Research
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports first-quarter 2024 earnings.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
What's in Store for Biogen (BIIB) This Earnings Season?
by Zacks Equity Research
Biogen's (BIIB) sales in the first quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have been moderate.
J&J (JNJ) to Begin Pharma Q1 Earnings Season: What's in Store?
by Zacks Equity Research
J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.
Will Novavax's (NVAX) Strategic Reshaping Curb Cash Burn?
by Zacks Equity Research
To extend its existing cash runway and curb cash burn, Novavax (NVAX) initiates multiple restructuring initiatives that are aimed at lowering operating expenses and enhancing profitability.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Novavax (NVAX) Down 3.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Moderna (MRNA) Posts Upbeat Data From Next-Gen COVID Jab Study
by Zacks Equity Research
Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID vaccine induces a more robust immune response compared with its previously approved bivalent COVID vaccine.
Novavax (NVAX) Q4 Earnings & Sales Miss Estimates, Stock Tanks
by Zacks Equity Research
Novavax's (NVAX) fourth-quarter earnings and revenues miss estimates. Stock tanks on moderate revenue guidance for 2024.
Novavax (NVAX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Novavax (NVAX) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Novavax (NVAX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Novavax (NVAX) delivered earnings and revenue surprises of -193.88% and 12.89%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Novavax (NVAX) Surges 8.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Novavax (NVAX) Q4 Earnings Preview: What's in the Cards?
by Zacks Equity Research
Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novavax's (NVAX) Updated COVID Jab Gets WHO Nod for Emergency Use
by Zacks Equity Research
Following this authorization, Novavax's (NVAX) updated COVID-19 vaccine is available as an option to all 194 WHO member states.